Structural basis for allosteric, substratedependent stimulation of SIRT1 activity by resveratrol

Genes and Development

Volumn 29, Issue 12, 2015, Pages 1316-1325

  Cao, Duanfang ^a,b   Wang, Mingzhu ^a   Qiu, Xiayang ^c   Liu, Dongxiang ^d   Jiang, Hualiang ^d   Yang, Na ^a   Xu, Rui Ming ^a,b  

^a INSTITUTE OF BIOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Histone; Protein deacetylase; Resveratrol; Sirtuins; Structure

Indexed keywords

7 AMINO 4 METHYLCOUMARIN; COUMARIN DERIVATIVE; RESVERATROL; SIRTUIN 1; UNCLASSIFIED DRUG; STILBENE DERIVATIVE;

ALLOSTERISM; ARTICLE; BIOLOGICAL FUNCTIONS; CARBOXY TERMINAL SEQUENCE; CELL STIMULATION; CELL STRUCTURE; CLINICAL EFFECTIVENESS; ENZYME ACTIVITY; ENZYME MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; DRUG EFFECTS; ENZYME ACTIVATION; ISOLATION AND PURIFICATION; METABOLISM; PROTEIN TERTIARY STRUCTURE;

CRYSTALLIZATION; ENZYME ACTIVATION; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; SIRTUIN 1; STILBENES;

EID: 84933524839     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.265462.115     Document Type: Article

References (54)

1. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-KunstleveRW, et al. 2010. Phenix: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
2. Avalos JL, Celic I, Muhammad S, Cosgrove MS, Boeke JD, Wolberger C. 2002. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol Cell 10: 523-535.
3. Baur JA. 2010. Biochemical effects of SIRT1 activators. Biochim Biophys Acta 1804: 1626-1634.
4. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M. 2009. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74: 619-624.
5. Bemis JE, Vu CB, Xie R, Nunes JJ, Ng PY, Disch JS, Milne JC, Carney DP,LynchAV, Jin L, et al. 2009. Discoveryof oxazolo[4,5-b] pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg Med Chem Lett 19: 2350-2353.
6. Borra MT, Smith BC, Denu JM. 2005. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280: 17187-17195.
7. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, et al. 2004. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015.
8. Dai H, Kustigian L, Carney D, Case A, Considine T, Hubbard BP, Perni RB, Riera TV, Szczepankiewicz B, Vlasuk GP, et al. 2010. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 285: 32695-32703.
9. Davenport AM, Huber FM, Hoelz A. 2014. Structural and functional analysis of human SIRT1. J Mol Biol 426: 526-541.
10. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
11. Feldman JL, Dittenhafer-Reed KE, Denu JM. 2012. Sirtuin catalysis and regulation. J Biol Chem 287: 42419-42427.
12. Finnin MS, Donigian JR, Pavletich NP. 2001. Structure of the histone deacetylase SIRT2. Nat Struct Biol 8: 621-625.
13. Frye RA. 2000. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 273: 793-798.
14. Garrity J, Gardner JG, Hawse W, Wolberger C, Escalante-Semerena JC. 2007. N-lysine propionylation controls the activity of propionyl-CoA synthetase. J Biol Chem 282: 30239-30245.
15. Gertz M, Nguyen GT, Fischer F, Suenkel B, Schlicker C, Franzel B, Tomaschewski J, Aladini F, Becker C,Wolters D, et al. 2012. A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One 7: e49761.
16. Guarente L. 2011. Franklin H. Epstein lecture: sirtuins, aging, and medicine. N Engl J Med 364: 2235-2244.
17. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, et al. 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
18. Hsu HC, Wang CL, Wang M, Yang N, Chen Z, Sternglanz R, Xu RM. 2013. Structural basis for allosteric stimulation of Sir2 activity by Sir4 binding. Genes Dev 27: 64-73.
19. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, Lamming DW, et al. 2013. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339: 1216-1219.
20. Imai S, Armstrong CM, Kaeberlein M, Guarente L. 2000. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403: 795-800.
21. Jin L,WeiW, Jiang Y, Peng H, Cai J, Mao C, Dai H, ChoyW, Bemis JE, Jirousek MR, et al. 2009. Crystal structures of human SIRT3 displaying substrate-induced conformational changes. J Biol Chem 284: 24394-24405.
22. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, Napper A, Curtis R, DiStefano PS, Fields S, et al. 2005. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280: 17038-17045.
23. Kang H, Suh JY, Jung YS, Jung JW, Kim MK, Chung JH. 2011. Peptide switch is essential for Sirt1 deacetylase activity. Mol Cell 44: 203-213.
24. Kim EJ, Kho JH, Kang MR,UmSJ. 2007. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 28: 277-290.
25. Lakshminarasimhan M, Rauh D, Schutkowski M, Steegborn C. 2013. Sirt1 activation by resveratrol is substrate sequenceselective. Aging (Albany NY) 5: 151-154.
26. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L, Sternglanz R. 2000. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci 97: 5807-5811.
27. Liu B, Ghosh S, Yang X, Zheng H, Liu X,Wang Z, Jin G, Zheng B, Kennedy BK, Suh Y, et al. 2012. Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathy-based progeria. Cell Metab 16: 738-750.
28. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W. 2001. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107: 137-148.
29. McCoy AJ, Grosse-Kunstleve RW, Adams PD,Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
30. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, et al. 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716.
31. Min J, Landry J, Sternglanz R, Xu RM. 2001. Crystal structure of a SIR2 homolog-NAD complex. Cell 105: 269-279.
32. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y, McBurney M, Guarente L. 2004. Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551-563.
33. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
34. Nguyen GT, Gertz M, Steegborn C. 2013. Crystal structures of Sirt3 complexes with 4′-bromo-resveratrol reveal binding sites and inhibition mechanism. Chem Biol 20: 1375-1385.
35. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276: 307-326.
36. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, et al. 2010. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340-8351.
37. Pan PW, Feldman JL, Devries MK, Dong A, Edwards AM, Denu JM. 2011. Structure and biochemical functions of SIRT6. J Biol Chem 286: 14575-14587.
38. Pan M, Yuan H, Brent M, Ding EC, Marmorstein R. 2012. SIRT1 contains N-and C-terminal regions that potentiate deacetylase activity. J Biol Chem 287: 2468-2476.
39. Rodgers JT, Lerin C, HaasW, Gygi SP, Spiegelman BM, Puigserver P. 2005. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434: 113-118.
40. Sanders BD, Jackson B, Marmorstein R. 2010. Structural basis for sirtuin function: what we know and what we don't. Biochim Biophys Acta 1804: 1604-1616.
41. Sauve AA, Celic I, Avalos J, Deng H, Boeke JD, Schramm VL. 2001. Chemistry of gene silencing: the mechanism of NAD+-dependent deacetylation reactions. Biochemistry 40: 15456-15463.
42. Sauve AA, Moir RD, Schramm VL,Willis IM. 2005. Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol Cell 17: 595-601.
43. Sauve AA, Wolberger C, Schramm VL, Boeke JD. 2006. The biochemistry of sirtuins. Annu Rev Biochem 75: 435-465.
44. +-dependent deacetylase SIRT5 by suramin. Structure 15: 377-389.
45. Sinclair DA, Guarente L. 2014. Small-molecule allosteric activators of sirtuins. Annu Rev Pharmacol Toxicol 54: 363-380.
46. +-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci 97: 6658-6663.
47. Smith BC, Hallows WC, Denu JM. 2009. A continuous microplate assay for sirtuins and nicotinamide-producing enzymes. Anal Biochem 394: 101-109.
48. Tanner KG, Landry J, Sternglanz R, Denu JM. 2000. Silent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci 97: 14178-14182.
49. Tanny JC, Moazed D. 2001. Coupling of histone deacetylation to NAD breakdown by the yeast silencing protein Sir2: evidence for acetyl transfer from substrate to an NAD breakdown product. Proc Natl Acad Sci 98: 415-420.
50. Tanny JC, Kirkpatrick DS, Gerber SA, Gygi SP, Moazed D. 2004. Budding yeast silencing complexes and regulation of Sir2 activity by protein-protein interactions. Mol Cell Biol 24: 6931-6946.
51. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. 2004. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 16: 93-105.
52. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159.
53. Zhao K, Chai X, Marmorstein R. 2003. Structure of the yeast Hst2 protein deacetylase in ternary complex with 2′-Oacetyl ADP ribose and histone peptide. Structure 11: 1403-1411.
54. +) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition. J Med Chem 56: 963-969.